Introduction
============

Fixed drug eruption (FDE) is characterized by recurrent well-defined lesions in the same location each time the responsible drug is taken. We report here a rare case of FDE induced by atenolol, a beta-adrenoreceptor-blocking agent.

Case study
==========

A 48-year-old Tunisian woman was referred to our department for the appearance of five inflammatory plaques on both legs. She had been treated for hypertension with atenolol (Hypoten^®^, Al-Hikma Pharmaceuticals, Jordan) 100 mg once a day for six weeks. No other medications had been taken and she had not previously received beta-blocking agents. The lesions had begun three weeks after the onset of atenolol. Physical examination revealed five well-demarcated reddish and round plaques with an itching and burning sensation on both legs ([Figure 1](#f1-ccid_4057_fixed_drug_eruption){ref-type="fig"}). One of these lesions showed vesicular changes. The diagnosis of multiple FDE was suspected and atenolol was discontinued. Skin biopsy, taken from a lesion with no vesicular changes, showed focal necrosis of keratinocytes, hydropic degeneration of the basal cells, dermal edema and a perivascular lymphocytic infiltrate of the upper dermis. These histopathological findings were consistent with the diagnosis of FDE. Topical desonide (Locatop^®^) was applied twice a day and skin lesions resolved within two weeks with a residual pigmentation. 6 weeks after complete resolution, patch testing was carried out according to the International Contact Dermatitis Research Group ([@b3-ccid_4057_fixed_drug_eruption]) recommendations with 10% atenolol in petrolatum on a previously affected site of the right leg ([Figure 2](#f2-ccid_4057_fixed_drug_eruption){ref-type="fig"}) and on normal skin of the back. A positive reaction (++) was seen at D2 and D3 on the left leg but no reaction was detected on the back. Thus, the diagnosis of atenolol-induced FDE was established. There was no relapse during a follow-up period of one year.

Discussion
==========

Several drugs can induce FDE. They mostly include nonsteroidal antiinflammatory drugs, nonopioid analgesics, sulphonamides, and tetracyclines ([@b8-ccid_4057_fixed_drug_eruption]).

Topical provocation testing has been reported to be useful and safe for the diagnosis of FDE when applied on previously affected sites ([@b2-ccid_4057_fixed_drug_eruption]; [@b1-ccid_4057_fixed_drug_eruption]; [@b4-ccid_4057_fixed_drug_eruption]; [@b6-ccid_4057_fixed_drug_eruption]). Patch testing in FDE is still not standardized ([@b5-ccid_4057_fixed_drug_eruption]). Different patch test methods (open/occlusive) and variations in their evaluation (erythema of more than six hours duration/erythema and infiltration) exist ([@b5-ccid_4057_fixed_drug_eruption]).

Beta-blockers-induced FDE are very rare ([@b7-ccid_4057_fixed_drug_eruption]; [@b9-ccid_4057_fixed_drug_eruption]). Only two cases have been reported in the literature ([@b7-ccid_4057_fixed_drug_eruption]; [@b9-ccid_4057_fixed_drug_eruption]). They were induced by atenolol ([@b7-ccid_4057_fixed_drug_eruption]) and propranolol ([@b9-ccid_4057_fixed_drug_eruption]). None of them was confirmed by patch testing or systemic provocation ([@b7-ccid_4057_fixed_drug_eruption]; [@b9-ccid_4057_fixed_drug_eruption]). Thus, to the best of our knowledge, we report herein the first case of FDE induced by atenolol and confirmed by a positive patch test on previously affected sites.
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